Porcine Circoviruses Type 2 and 3 Chimeric Novel Vaccine Candidate Formed Virus-Like Particles and Induced Robust Immune Response in Mice.
Doan Thu-Dung TD, Pranoto Stella S, Tran Minh Tung MT, Gyawali Chet Narayan CN et al.
Porcine circovirus (PCV)-associated disease (PCVAD) encompasses a range of clinical syndromes in pigs, including wasting, reproductive failure, enteritis, and respiratory disorders. These clinical manifestations are primarily associated with PCV type 2 (PCV2). However, the recently emerged PCV type 3 (PCV3) shares limited sequence identity with PCV2, which may explain the limited cross-protection provided by current PCV2-based commercial vaccines. In this study, we developed and evaluated a novel chimeric vaccine candidate targeting both PCV2 and PCV3. A chimeric capsid protein (rCapC) was rationally designed by replacing the decoy epitope and CD-loop region of the PCV2 capsid with a type-specific epitope derived from PCV3. The recombinant protein was expressed using a baculovirus expression system and verified by sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE) and Western blot analysis. rCapC was predominantly detected in the insoluble fraction of Sf9 insect cell lysates and was capable of self-assembling into virus-like particles (VLPs), as confirmed by transmission electron microscopy (TEM). The antigenicity of rCapC was demonstrated by an in vitro Western blot assay, showing specific reactivity with antibodies from PCV2-infected pigs. Immunization studies in mice revealed that rCapC elicited strong and sustained humoral immune responses, persisting for up to 16 weeks post-vaccination. Notably, the chimeric protein induced antigen-specific anti-PCV2 and anti-PCV3 binding antibody responses at low antigen doses (5-25 µg per dose). These findings indicate that rCapC is a promising chimeric VLP-based vaccine candidate capable of inducing robust bivalent humoral and cellular immune responses against both PCV2 and PCV3 Cap antigens.